HSBC Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.54M | Hold |
2,000
| – | – | ﹤0.01% | 1646 |
|
|
2025
Q4 | $1.55M | Sell |
2,000
-3,900
| -66% | -$2.65M | ﹤0.01% | 1694 |
|
|
2025
Q3 | $3.32M | Buy |
5,900
+4,700
| +392% | +$2.66M | ﹤0.01% | 1333 |
|
|
2025
Q2 | $629K | Hold |
1,200
| – | – | ﹤0.01% | 2036 |
|
|
2025
Q1 | $761K | Sell |
1,200
-11,700
| -91% | -$8.05M | ﹤0.01% | 1875 |
|
|
2024
Q4 | $9.14M | Buy |
12,900
+2,800
| +28% | +$2.35M | 0.01% | 954 |
|
|
2024
Q3 | $10.6M | Sell |
10,100
-11,300
| -53% | -$12.6M | 0.01% | 906 |
|
|
2024
Q2 | $22.4M | Sell |
21,400
-3,800
| -15% | -$3.68M | 0.01% | 655 |
|
|
2024
Q1 | $24.3M | Buy |
25,200
+8,300
| +49% | +$7.89M | 0.02% | 643 |
|
|
2023
Q4 | $14.9M | Sell |
16,900
-6,500
| -28% | -$5.35M | 0.01% | 758 |
|
|
2023
Q3 | $19.4M | Buy |
23,400
+500
| +2% | +$393K | 0.02% | 635 |
|
|
2023
Q2 | $16.3M | Buy |
22,900
+13,500
| +144% | +$10.4M | 0.02% | 673 |
|
|
2023
Q1 | $7.64M | Buy |
9,400
+6,000
| +176% | +$4.53M | 0.01% | 958 |
|
|
2022
Q4 | $2.45M | Sell |
3,400
-1,900
| -36% | -$1.4M | ﹤0.01% | 1595 |
|
|
2022
Q3 | $3.66M | Buy |
5,300
+2,800
| +112% | +$1.76M | 0.01% | 1305 |
|
|
2022
Q2 | $1.49M | Sell |
2,500
-700
| -22% | -$455K | ﹤0.01% | 1731 |
|
|
2022
Q1 | $2.24M | Sell |
3,200
-2,900
| -48% | -$1.83M | ﹤0.01% | 1558 |
|
|
2021
Q4 | $3.87M | Buy |
6,100
+300
| +5% | +$184K | ﹤0.01% | 1381 |
|
|
2021
Q3 | $3.52M | Buy |
5,800
+4,200
| +263% | +$2.61M | ﹤0.01% | 1305 |
|
|
2021
Q2 | $894K | Buy |
1,600
+300
| +23% | +$152K | ﹤0.01% | 1825 |
|
|
2021
Q1 | $615K | Sell |
1,300
-25,400
| -95% | -$12.4M | ﹤0.01% | 1860 |
|
|
2020
Q4 | $12.7M | Buy |
26,700
+8,000
| +43% | +$4.32M | 0.02% | 722 |
|
|
2020
Q3 | $10.6M | Buy |
18,700
+5,000
| +36% | +$3.03M | 0.02% | 697 |
|
|
2020
Q2 | $8.54M | Buy |
13,700
+13,400
| +4,467% | +$7.61M | 0.02% | 691 |
|
|
2020
Q1 | $145K | Sell |
300
-52,300
| -99% | -$21.6M | ﹤0.01% | 2394 |
|
|
2019
Q4 | $19.7M | Buy |
52,600
+29,100
| +124% | +$9.79M | 0.03% | 527 |
|
|
2019
Q3 | $6.52M | Sell |
23,500
-200
| -0.8% | -$59.2K | 0.01% | 1057 |
|
|
2019
Q2 | $7.42M | Hold |
23,700
| – | – | 0.01% | 978 |
|
|
2019
Q1 | $9.73M | Sell |
23,700
-5,600
| -19% | -$2.31M | 0.02% | 821 |
|
|
2018
Q4 | $10.9M | Buy |
29,300
+6,700
| +30% | +$2.45M | 0.02% | 780 |
|
|
2018
Q3 | $9.13M | Buy |
22,600
+1,400
| +7% | +$533K | 0.01% | 893 |
|
|
2018
Q2 | $7.31M | Hold |
21,200
| – | – | 0.01% | 944 |
|
|
2018
Q1 | $7.3M | Buy |
+21,200
| New | +$7.37M | 0.01% | 952 |
|
|
2017
Q4 | – | Sell |
-17,800
| Closed | -$7.96M | – | 2329 |
|
|
2017
Q3 | $7.96M | Buy |
17,800
+11,900
| +202% | +$5.66M | 0.01% | 878 |
|
|
2017
Q2 | $2.9M | Buy |
+5,900
| New | +$2.58M | 0.01% | 1155 |
|
|
2016
Q3 | – | Sell |
-5,000
| Closed | -$1.75M | – | 2106 |
|
|
2016
Q2 | $1.75M | Hold |
5,000
| – | – | ﹤0.01% | 1219 |
|
|
2016
Q1 | $1.8M | Hold |
5,000
| – | – | 0.01% | 1171 |
|
|
2015
Q4 | $2.71M | Buy |
+5,000
| New | +$2.71M | 0.01% | 1164 |
|
Other funds holding REGN
VCM
N
HSBC Holdings's REGN Position: Q1 2026 in Review
HSBC Holdings increased its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, buying an estimated $3.47M and bringing the position to 323,338 shares worth $250M. The position accounts for 0.13% of the portfolio, ranked #148.
HSBC Holdings first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $384M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- HSBC Holdings held 323,338 shares of Regeneron Pharmaceuticals worth $250M as of Q1 2026.
- HSBC Holdings bought 4,530 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.47M.
- Regeneron Pharmaceuticals made up 0.13% of HSBC Holdings's portfolio in Q1 2026, its #148 holding.
- HSBC Holdings first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- HSBC Holdings's Regeneron Pharmaceuticals position peaked at $384M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.